Clinical bottom line
Circulating tumor DNA (ctDNA) dynamics represent a promising biomarker for the early detection of treatment resistance and disease progression in metastatic breast cancer (MBC). Serial monitoring of ctDNA can potentially identify molecular changes preceding radiographic or clinical relapse, enabling timely therapeutic adjustments. However, the clinical utility of ctDNA kinetics to guide management decisions remains investigational and requires further validation in prospective trials. Clinicians should consider ctDNA dynamics as a complementary tool to standard imaging and clinical assessment rather than a standalone indicator at present.
What the evidence shows
Recent advances in ctDNA detection technologies have improved sensitivity and specificity for tracking tumor-derived genetic alterations in plasma from patients with MBC (Liao et al., 2020). Studies demonstrate that rising ctDNA levels or emergence of resistance-associated mutations often precede radiologic progression by weeks to months, offering a potential lead time for intervention (Amato et al., 2024). For example, serial ctDNA monitoring can reveal acquired ESR1 mutations conferring endocrine resistance or PIK3CA mutations linked to targeted therapy failure, informing therapeutic strategy shifts (Ghanim Taki et al., 2026).
Meta-analyses and systematic reviews underscore that ctDNA dynamics correlate with progression-free survival and overall survival, suggesting prognostic value (Amato et al., 2024). Moreover, ctDNA clearance during treatment is associated with better outcomes, while persistent or increasing ctDNA signals treatment resistance (Ghanim Taki et al., 2026). These findings support ctDNA as a real-time biomarker reflecting tumor burden and clonal evolution in MBC.
However, the evidence base is largely composed of observational cohorts and retrospective analyses. Prospective interventional trials using ctDNA-guided treatment modifications are limited but emerging, aiming to demonstrate improved clinical outcomes through earlier detection of resistance (Amato et al., 2024). Current clinical guidelines acknowledge ctDNA testing as an adjunctive tool but do not yet recommend routine use for treatment decision-making in MBC.
Caveats and uncertainty
Several challenges limit immediate clinical implementation of ctDNA dynamics monitoring. Analytical variability exists across platforms regarding sensitivity, mutation panels, and quantification methods, complicating standardization (Liao et al., 2020). Low tumor shedding or low ctDNA levels in some patients reduce detection reliability, especially in bone-predominant or indolent disease.
Interpretation of ctDNA changes requires caution; transient fluctuations may not always signify true progression. The optimal frequency and timing of ctDNA sampling remain undefined. Additionally, the clinical benefit of acting on ctDNA-detected resistance before radiologic progression is unproven and may risk overtreatment or unnecessary toxicity.
Biological heterogeneity of MBC and tumor evolution can result in discordance between ctDNA findings and imaging or clinical status. Integration with other biomarkers and clinical context is essential. Finally, cost-effectiveness and accessibility of serial ctDNA testing in routine practice need evaluation.
How this may change practice
As evidence matures, ctDNA dynamics could become a valuable tool for personalized management of MBC by enabling earlier detection of resistance and guiding timely therapy changes. Incorporation of ctDNA monitoring into clinical workflows may optimize treatment sequencing, minimize ineffective therapies, and improve outcomes.
Clinicians should stay informed about emerging data and evolving guidelines regarding ctDNA use. In selected patients, particularly those with high-risk or rapidly progressing disease, ctDNA testing may complement imaging and clinical assessment to refine prognosis and detect molecular resistance mechanisms.
Future integration of ctDNA with other liquid biopsy components and multi-omics approaches may enhance precision oncology strategies. Ultimately, prospective trials demonstrating that ctDNA-guided interventions improve survival and quality of life are needed before widespread adoption.